CORRECTED-Novartis says 82 pct of leukemia patients in remission after CAR-T

Dec 3 (Reuters) - An experimental cancer therapy being

developed by Novartis AG eliminated an aggressive form

of blood cancer in 82 percent of children and young adults

treated with modified immune cells in a mid-stage trial, the

company said on Saturday.

Read more